Trv Gp Ii 13F annual report

Trv Gp Ii is an investment fund managing more than $1.34 million ran by Kevin Gillis. There is currently 1 company in Mr. Gillis’s portfolio. The largest and only investment include Jounce Therapeutics Inc worth $1.34 million.

$1.34 million Assets Under Management (AUM)

As of 27th October 2022, Trv Gp Ii’s top holding is 572,829 shares of Jounce Therapeutics Inc currently worth over $1.34 million and making up 100.0% of the portfolio value. Relative to the number of outstanding shares of Jounce Therapeutics Inc, Trv Gp Ii owns more than approximately 0.1% of the company.

Currently, Trv Gp Ii's portfolio is worth at least $1.34 million. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Trv Gp Ii

The Trv Gp Ii office and employees reside in Boston, Massachusetts. According to the last 13-F report filed with the SEC, Kevin Gillis serves as the Chief Operating Officer at Trv Gp Ii.

Recent trades

There are companies that Trv Gp Ii is getting rid of from its portfolio. Trv Gp Ii closed its position in Allena Pharmaceuticals Inc on 3rd November 2022. It sold the previously owned 2,790,964 shares for $645 thousand. Kevin Gillis also disclosed a decreased stake in Jounce Therapeutics Inc by 0.6%. This leaves the value of the investment at $1.34 million and 572,829 shares.

One of the smallest hedge funds

The two most similar investment funds to Trv Gp Ii are Abg Innovation Capital Partners Iii Gp Ltd and Light Sky Macro L.P.. They manage $1.34 million and $1.35 million respectively.

Kevin Gillis investment strategy

Trv Gp Ii’s portfolio is diversified across 1 sector. Currently, their heaviest sector is Health Care — making up 100.0% of the total portfolio value. The fund focuses on investments in the United States as 100.0% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are large-cap stocks. Stocks with a size of more than $10 billion in market cap make up approximately 0.1% of the total holdings value. On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio. The average market cap of the portfolio companies is close to $107 million.

The complete list of Trv Gp Ii trades based on 13F SEC filings

These positions were updated on November 3rd based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security	Shares Owned	Value	Allocation
Jounce Therapeutics Inc	57.50% 572,829	$1,340,000	100.00%
Allena Pharmaceuticals Inc	Closed 2,790,964	$645,000
No transactions found
Showing first 500 out of 2 holdings